Suven Life Sciences financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹3.6cr+91.0% on Q1 FY26
Net profit
−₹128cr−₹51.5 cr in Q1 FY26
EBITDA margin
−3,715.9%−997.3 pts on Q1 FY26
EPS
−₹4.84−₹2.36 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue3.61.9+91.0%
EBITDA−133−50.7—
EBITDA margin−3,715.9%−2,718.6%−997.3 pts
Profit before tax−128−51.5—
Net profit−128−51.5—
EPS−₹4.84−₹2.36—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹3.6 crNet profit₹−128 crNet margin−3,578.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
7,069————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
8.38.337.390.983.4
7,061————
8.87.16.711.713.5
—+6.9%−43.1%−13.6%—
−366−285−166−128−126
−4,155.5%−3,998.8%−2,490.7%−1,094.7%−929.8%
−373−290−172−135−132
−352−276−161−105−118
−3,998.7%−3,884.1%−2,415.1%−898.6%−873.5%
−₹13.36−₹10.48−₹6.10−₹3.98−₹4.48
—−71.9%−53.0%+11.2%—
—−302−154−82.6−208
—−5.1−37.3−2.4−2.9
−307−307−191−85.0−211
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹268.05

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹7,069 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————7,069.0
- Cash, Equiv & ST Investments83.490.937.38.38.3
Enterprise Value————7,060.7
Revenue13.511.76.77.18.8
Growth %, YoY—-13.6-43.1+6.9—
EBITDA-125.9-128.0-165.8-284.5-366.3
Margin %-929.78-1,094.72-2,490.66-3,998.80-4,155.50
EBIT-132.4-134.5-171.6-290.1-372.7
Net Income-118.3-105.1-160.7-276.3-352.4
Margin %-873.52-898.63-2,415.11-3,884.13-3,998.70
EPS, Adj (current shares)-4.48-3.98-6.10-10.48-13.36
Growth %, YoY—+11.2-53.0-71.9—
Cash from Operations-207.9-82.6-154.1-301.8—
Capital Expenditures-2.9-2.4-37.3-5.1—
Free Cash Flow-210.8-85.0-191.4-306.9-306.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Suven Life Sciences financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Suven Life Sciences (NSE: SUVEN) had a market capitalisation of ₹6,975 crore at the 29 October 2026 close (₹264.20 a share) and a price-to-book ratio of 11.79. In FY26 its consolidated net loss was ₹276 crore on revenue of ₹7.1 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹128 crore. It had no borrowings on 31 March 2026. Promoters held 65.47% of the shares on 30 September 2026.

Share price used
₹264.20 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Suven Life Sciences at a glance · consolidated

Market cap
₹6,975 Crat ₹264.20 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
11.79book value ₹22.40 a share
ROE (FY26)
−78.8%+5.8 pts vs FY25ROCE −82.3%
Debt to equity
0.00net cash ₹337 Cr
Promoter holding
65.47%−4.6 pts vs 30 Jun 202630 September 2026
Net worth
₹591 Cr+437.7% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹307 Cr
EPS (FY26)
−₹12.13

Questions

What is the Suven Life Sciences PE ratio today?

Suven Life Sciences' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹352 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹6,975 crore at ₹264.20 a share.

What is the Suven Life Sciences PB ratio (price to book value)?

Suven Life Sciences' price-to-book (PB) ratio is 11.79 at the 29 October 2026 close: a market capitalisation of ₹6,975 crore divided by shareholders' equity (book value) of ₹591 crore on 31 March 2026. That is a book value of ₹22.40 per share against a share price of ₹264.20.

What is the Suven Life Sciences ROE and ROCE?

In FY26, Suven Life Sciences' return on equity (ROE) was −78.8% and its return on capital employed (ROCE) was −82.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −84.6% and ROCE −89.6%.

What is the Suven Life Sciences market cap?

Suven Life Sciences' market capitalisation was ₹6,975 crore at the 29 October 2026 close: 26.4 crore shares at ₹264.20 each.

Is Suven Life Sciences debt free?

Yes. Suven Life Sciences had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹337 crore of cash, bank balances and current investments.

What is the Suven Life Sciences debt to equity ratio?

Suven Life Sciences' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹591 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Suven Life Sciences net worth?

Suven Life Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹591 crore on 31 March 2026, up 437.7% from ₹110 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹6,975 crore at the 29 October 2026 close.

What is the Suven Life Sciences book value per share?

Suven Life Sciences' book value per share was ₹22.40 on 31 March 2026: shareholders' equity of ₹591 crore divided by the 26.4 crore shares in issue. The share price at the 29 October 2026 close was ₹264.20.

What is the Suven Life Sciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Suven Life Sciences' consolidated net loss was ₹276 crore, wider than the loss of ₹161 crore in FY25, on revenue from operations of ₹7.1 crore (up 6.9%).

What is the Suven Life Sciences EPS?

Suven Life Sciences' basic earnings per share (EPS) were −₹12.13 in FY26, against −₹7.37 in FY25.

What is the Suven Life Sciences promoter holding?

Promoters held 65.47% of Suven Life Sciences on 30 September 2026, down 4.61 percentage points from 70.08% the previous quarter and down 1.89 percentage points from 67.36% a year earlier, according to the shareholding pattern filed with NSE.

When are the Suven Life Sciences next results?

Suven Life Sciences will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Suven Life Sciences shareholding pattern?

On 30 September 2026, Suven Life Sciences' shares were held by promoters 65.47%, foreign portfolio investors (FII/FPI) 0.46%, domestic institutions (DII) 2.17% (including mutual funds at 0.08%) and retail and other non-institutional investors 31.90%. Over the year, FII holding was down 0.72 percentage points from 1.18% and DII holding was down 1.22 percentage points from 3.39%.

How does Suven Life Sciences compare with its peers?

On FY26 consolidated figures, against TAKE: Suven Life Sciences' operating margin of −4,077.7% is the lower of the two (TAKE −3.6%; peer average −3.6%); its return on equity of −78.8% is the lower of the two (TAKE 42.1%; peer average 42.1%); its revenue growth over three years of −19.3% a year is the higher of the two (TAKE −34.1% a year; peer average −34.1% a year).

Suven Life Sciences vs TAKE: how do they compare?

In FY26, Suven Life Sciences earned net profit of ₹276 crore on revenue of ₹7.1 crore, against ₹10.8 crore on ₹54.2 crore for TAKE. Suven Life Sciences' operating margin was −4,077.7% (TAKE −3.6%) and its return on equity −78.8% (TAKE 42.1%). At the 29 October 2026 close, Suven Life Sciences' market capitalisation was ₹6,975 crore against ₹164 crore for TAKE.

What is the Suven Life Sciences free cash flow?

In FY26, Suven Life Sciences generated ₹302 crore of cash from operations and spent ₹5.1 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹307 crore. In FY25 it was −₹191 crore.

What are the Suven Life Sciences latest quarterly results?

Suven Life Sciences' latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net loss ₹128 crore, wider than the loss of ₹51.5 crore in Q1 FY26; revenue from operations ₹3.6 crore, up 91.0% year on year.

Where do these Suven Life Sciences figures come from?

From Suven Life Sciences' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.